Thermo Fisher Scientific Inc., one of the world’s top life science company opens it U.S. Precision Medicine Science Center (PMSC) in Cambridge, Mass.
This facility beholds technologies that addresses collaborators need of analytical workflows which can generate precise molecular profiles of patients. This data will ultimately complement collaborators quest to treat disease effectively in clinical set-ups.
The centre also houses best in class experts who can help current and potential clients expedite journey from biomarker discovery to assay development. Company intends to achieve this by compressing R&D timelines.
“For health and science innovators, a bottleneck exists today between the discovery of biomarkers and their widespread use at the point of care,” said Emily Chen, senior director, Thermo Fisher Precision Medicine Science Center. “Our goal at the PMSC is to remove that bottleneck and help scientists and physicians reduce the time it takes to demonstrate clinic validity and utility.”
“Precision medicine needs to be based on high-quality data, and proteomics is central to that,” said PMSC collaborator Jennifer Van Eyk, PhD, Cedars-Sinai Medical Center in Los Angeles. “Our work with the team at the PMSC is helping us accelerate the important journey from discovery to patient care.”
This is not first time that company has opened PMSC centre, Thermofisher in past has opened similar centre in China that looks to address same challenges.
This 20 billion dollar sales company has unique blend of services that range from life science research to patient diagnostics, stretching far beyond to laboratory offerings. It is this combination that has positioned the company to forefront of innovation, which is well reflected in its global strategic decisions. For more updates on Thermo fisher and its peers, follow Pharmed Intel.